JP2011530537A5 - - Google Patents

Download PDF

Info

Publication number
JP2011530537A5
JP2011530537A5 JP2011522303A JP2011522303A JP2011530537A5 JP 2011530537 A5 JP2011530537 A5 JP 2011530537A5 JP 2011522303 A JP2011522303 A JP 2011522303A JP 2011522303 A JP2011522303 A JP 2011522303A JP 2011530537 A5 JP2011530537 A5 JP 2011530537A5
Authority
JP
Japan
Prior art keywords
sequence
cap03
another embodiment
dna
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011522303A
Other languages
English (en)
Japanese (ja)
Other versions
JP5583667B2 (ja
JP2011530537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/053264 external-priority patent/WO2010017544A2/en
Publication of JP2011530537A publication Critical patent/JP2011530537A/ja
Publication of JP2011530537A5 publication Critical patent/JP2011530537A5/ja
Application granted granted Critical
Publication of JP5583667B2 publication Critical patent/JP5583667B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011522303A 2008-08-08 2009-08-10 長時間作用型ｄｎａデンドリマーおよびその方法 Active JP5583667B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18831808P 2008-08-08 2008-08-08
US61/188,318 2008-08-08
PCT/US2009/053264 WO2010017544A2 (en) 2008-08-08 2009-08-10 Long-acting dna dendrimers and methods thereof

Publications (3)

Publication Number Publication Date
JP2011530537A JP2011530537A (ja) 2011-12-22
JP2011530537A5 true JP2011530537A5 (enExample) 2012-03-15
JP5583667B2 JP5583667B2 (ja) 2014-09-03

Family

ID=41664237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011522303A Active JP5583667B2 (ja) 2008-08-08 2009-08-10 長時間作用型ｄｎａデンドリマーおよびその方法

Country Status (7)

Country Link
US (1) US20120122800A1 (enExample)
EP (2) EP2657342B1 (enExample)
JP (1) JP5583667B2 (enExample)
AU (1) AU2009279458B2 (enExample)
CA (1) CA2731521C (enExample)
IL (1) IL210841A (enExample)
WO (1) WO2010017544A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110206611A1 (en) 2010-02-24 2011-08-25 Genisphere, Llc DNA Dendrimers as Thermal Ablation Devices
US20140228234A1 (en) 2011-06-15 2014-08-14 Naomi B. Zak Target-recognition compositions comprising novel synthetic conjugates for trapping and diagnosis of a target molecule
HK1201486A1 (en) * 2011-10-25 2015-09-04 Arch Personal Care Products, L.P. Composition containing an extract of a sequential or simultaneous fermentation
US9651549B2 (en) * 2012-07-13 2017-05-16 Genisphere, Llc Lateral flow assays using DNA dendrimers
WO2014121050A1 (en) * 2013-02-01 2014-08-07 Genisphere, Llc Functionalized dna dendrimers for gene delivery to cells
JP6346265B2 (ja) 2013-03-21 2018-06-20 ジェニスフィア・エルエルシー Ｄｎａインターカレーティング剤の細胞送達
EP3289084B1 (en) * 2015-04-17 2020-09-16 Genisphere, LLC siRNA INHIBITION OF HUMAN ANTIGEN R EXPRESSION FOR TREATMENT OF CANCER
JP2019513692A (ja) * 2016-02-19 2019-05-30 ジェニスフィア・エルエルシー 核酸キャリア及び治療上の使用方法
WO2017143156A1 (en) * 2016-02-19 2017-08-24 Genisphere Llc Nucleic acid carriers and therapeutic methods of use
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
CN118638787A (zh) 2017-12-06 2024-09-13 艾维迪提生物科学公司 治疗肌萎缩和强直性肌营养不良的组合物和方法
EP3759225A1 (en) 2018-03-02 2021-01-06 Sixfold Bioscience Ltd. Compositions for delivery of cargo to cells
JP7082659B2 (ja) * 2018-05-11 2022-06-08 中国塗料株式会社 防汚塗料組成物、防汚塗膜、防汚塗膜付き基材及び防汚方法
WO2021053405A2 (en) 2019-08-30 2021-03-25 Sixfold Bioscience Ltd. Compositions for transfer of cargo to cells
BR112021026769A2 (pt) * 2019-12-23 2022-07-26 Illumina Inc Nanopartícula com sítio único para fixação de polinucleotídeo-molde e métodos
TW202144572A (zh) 2020-03-19 2021-12-01 美商亞維代堤生物科學公司 治療臉肩胛肱骨肌肉失養症之組合物及方法
CN115997016A (zh) 2020-04-27 2023-04-21 西克斯福德生物科学有限公司 包含具有模块化官能团的核酸纳米颗粒的组合物
US12209266B2 (en) 2020-05-12 2025-01-28 Illumina, Inc. Generating nucleic acids with modified bases using recombinant terminal deoxynucleotidyl transferase
KR20230084520A (ko) * 2020-10-09 2023-06-13 스미토모 파마 가부시키가이샤 올리고 핵산 콘쥬게이트
EP4401792A4 (en) 2021-09-16 2025-12-03 Avidity Biosciences Inc COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY
EP4703381A1 (en) 2024-09-03 2026-03-04 Institució Catalana de Recerca i Estudis Avançats Antibodies against icam-1 and applications thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5175270A (en) 1986-09-10 1992-12-29 Polyprobe, Inc. Reagents for detecting and assaying nucleic acid sequences
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6117631A (en) 1996-10-29 2000-09-12 Polyprobe, Inc. Detection of antigens via oligonucleotide antibody conjugates
AU8601898A (en) 1997-07-29 1999-02-22 Polyprobe, Inc. Dendritic nucleic acids exhibiting maximal self-assembly
US20070173473A1 (en) * 2001-05-18 2007-07-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of proprotein convertase subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
US20040023248A1 (en) * 2001-12-07 2004-02-05 Whitehead Institiute For Biomedical Research Methods and reagents for improving nucleic acid detection
AU2003243562A1 (en) * 2002-06-12 2003-12-31 Datascope Investment Corp. Polymeric label molecules
US20070167384A1 (en) * 2003-04-02 2007-07-19 Dharmacon, Inc. Modified polynucleotides for use in rna interference
US7223544B2 (en) * 2003-06-27 2007-05-29 Cornell Research Foundation, Inc. Nucleic acid-engineered materials
WO2005113571A2 (en) * 2004-05-13 2005-12-01 The University Of North Carolina At Chapel Hill Methods for the delivery of oligomeric compounds
US8067572B2 (en) * 2005-05-25 2011-11-29 The University Of York Hybrid interfering RNA
US20100136614A1 (en) * 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
EP3351270A1 (en) * 2007-05-23 2018-07-25 The Trustees of the University of Pennsylvania Targeted carriers for intracellular drug delivery
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference

Similar Documents

Publication Publication Date Title
MX2024012513A (es) Composiciones y metodos de tratamiento de atrofia muscular y distrofia miotonica
JP2015518721A5 (enExample)
JP2013510561A5 (enExample)
JP2014509511A5 (enExample)
WO2009129319A3 (en) Silencing of csn5 gene expression using interfering rna
WO2011133886A3 (en) Production of heteromultimeric proteins
CN113330117A (zh) 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP2011529686A5 (enExample)
JP2009514877A5 (enExample)
JP2010273685A5 (enExample)
JP2017093448A5 (enExample)
WO2008092081A3 (en) Targeted delivery of sirna
JP2012505657A5 (enExample)
WO2008036406A3 (en) Compositions and methods related to protein displacement therapy for myotonic distrophy
JP2006525796A5 (enExample)
WO2010077422A3 (en) Formulations of single domain antigen binding molecules
JP2009516517A5 (enExample)
MX355255B (es) Variantes de fc y métodos para su producción.
JP2012504416A5 (enExample)
JP2008529500A5 (enExample)
WO2007127219A3 (en) Targeted delivery to leukocytes using protein carriers
MX2015005352A (es) Composiciones y métodos para el tratamiento de la enfermedad de parkinson mediante la administración selectiva de moléculas de oligonucleótidos a tipos específicos de neuronas.
JP2021167329A5 (enExample)
AR052441A1 (es) Suspension no acuosa inyectable
JP2014514921A5 (enExample)